Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

e accounts receivable 5,365 7,597 Decrease (increase) in inventories (4,073) 1,160 Decrease (increase) in prepaids and other assets 496 2,044 Increase (decrease) in accounts payable (8,095) (2,033) Increase (decrease) in accrued compensation (6,133) (3,932) Increase (decrease) in accrued clinical trial expenses (2,640) 86 Increase (decrease) in accrued expenses to contract manufacturers - (31,994) Increase (decrease) in accrued expenses 3,364 (123) Increase (decrease) in deferred revenue (3,029) (1,200) Increase (decrease) in other liabilities (1,897) (2,761) ------ ------ Net cash used in operating activities (42,394) (64,972) Cash flows from investing activities: Purchases of property and equipment (5,104) (5,281) Purchases of investments (85,298) (156,092) Maturities of investments 104,458 186,758 Transaction costs from Novartis pulmonary asset sale (4,766) - ------ --- Net cash provided by investing activities 9,290 25,385 Cash flows used in financing activities: Proceeds from issuances of common stock 61 371 Payments of loan and capital lease obligations (302) (411) ---- ---- Net cash used in financing activities
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... England, February 14 Executives from Senexis,and O2H, ... under which,O2H will provide synthetic and computational chemistry ... an FTE basis., "We believe our collaboration ... and will benefit our search for new,therapeutics to ...
... Feb. 14 AspenBio Pharma,Inc. (Nasdaq: APPY ) ... drugs and diagnostics for animals and humans, has been,invited ... Growth Stock,Conference. The conference will be held February 18-21, ... California., Roth Capital Partners Stock Conferences are one ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... quarter and full year 2007,financial results and provide a ... Eastern Time (2:00 p.m. Pacific Time). Financial results,for the ... be released,earlier that day., Interested parties may access ...
Cached Biology Technology:Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference 2Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2
(Date:4/23/2014)... is a technique used to read quickly. It ... skipping non-essential words and/ or sentences. Similarly to ... to quickly "read" genetic information. Genes that need ... the smaller the encoding message, the easier it ... from Instituto Gulbenkian de Cincia (IGC, Portugal) and ...
(Date:4/22/2014)... 2014) -- There are all sorts of signaling strategies ... their colorful tails; satin bowbirds build specialized stick structures, ... objects; and European bitterling males show off bright nuptial ... unique method to communicate with others. , ... can have profound fitness implications for individuals that are ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... 2013 Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), ... the medical and retail industries, announced that their patented software ... means to meet the priorities spelled out by the US ... United States Attorneys titled, "Guidance Regarding Marijuana ...
... flatworms have the remarkable ability to regrow any missing body ... the molecular basis of regeneration. Over the ... differ depending on the severity of the injury they suffer. ... wound reacts at the cellular and molecular levels quite differently ...
... to the origin of species as "that mystery of mysteries," ... cannot fully explain how new animals and plants arise. ... based on the assumption that the main cause of the ... formation of barriers to reproduction between populations. Those barriers ...
Cached Biology News:Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 2Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 3Tissue loss triggers regeneration in planarian flatworms 2Long-held assumption about emergence of new species questioned 2Long-held assumption about emergence of new species questioned 3
Vented Caps for 75 cm2 Flasks...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... Ciphergens ProteinChip System, Series 4000 incorporates ... clinical researchers and biologists in biomarker research. ... the fastest route for converting biomarker discoveries ... platform. The Series 4000 is designed to ...
Biology Products: